205 related articles for article (PubMed ID: 27127140)
41. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.
Enomoto Y; Kasai T; Takeda M; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Haratake J; Kojima Y; Ikeda N; Inatsugi N; Nonomura A
J Clin Pathol; 2012 Jun; 65(6):522-7. PubMed ID: 22412050
[TBL] [Abstract][Full Text] [Related]
42. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
43. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.
de Boer NL; van Kooten JP; Damhuis RAM; Aerts JGJV; Verhoef C; Madsen EVE
Ann Surg Oncol; 2019 Dec; 26(13):4222-4228. PubMed ID: 31620941
[TBL] [Abstract][Full Text] [Related]
44. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
Chou A; Toon CW; Clarkson A; Sheen A; Sioson L; Gill AJ
Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
[TBL] [Abstract][Full Text] [Related]
45. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
Kaya H; Sezgı C; Tanrıkulu AC; Taylan M; Abakay O; Sen HS; Abakay A; Kucukoner M; Kapan M
Neoplasma; 2014; 61(4):433-8. PubMed ID: 24645844
[TBL] [Abstract][Full Text] [Related]
46. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
[TBL] [Abstract][Full Text] [Related]
47. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
Soeberg MJ; Leigh J; Driscoll T; Armstrong B; Young JM; van Zandwijk N
Occup Environ Med; 2016 Mar; 73(3):187-94. PubMed ID: 26800709
[TBL] [Abstract][Full Text] [Related]
48. Identification of a mesothelioma phenotype.
Ohar JA; Ampleford EJ; Howard SE; Sterling DA
Respir Med; 2007 Mar; 101(3):503-9. PubMed ID: 16919927
[TBL] [Abstract][Full Text] [Related]
49. A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.
Desmeules P; Joubert P; Zhang L; Al-Ahmadie HA; Fletcher CD; Vakiani E; Delair DF; Rekhtman N; Ladanyi M; Travis WD; Antonescu CR
Am J Surg Pathol; 2017 Jul; 41(7):980-988. PubMed ID: 28505004
[TBL] [Abstract][Full Text] [Related]
50. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
[No Abstract] [Full Text] [Related]
51. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
52. [Molecular heterogeneity of malignant pleural mesotheliomas].
Tranchant R; Montagne F; Jaurand MC; Jean D
Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
[TBL] [Abstract][Full Text] [Related]
53. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Lund-Andersen C; Nakken S; Nygård S; Fromm B; Aasheim LB; Davidson B; Julsrud L; Abrahamsen TW; Kristensen AT; Dybdahl B; Larsen SG; Hovig E; Flatmark K
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30862609
[TBL] [Abstract][Full Text] [Related]
54. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma.
Paajanen J; Bueno R; De Rienzo A
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362209
[TBL] [Abstract][Full Text] [Related]
55. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.
Quetel L; Meiller C; Assié JB; Blum Y; Imbeaud S; Montagne F; Tranchant R; de Wolf J; Caruso S; Copin MC; Hofman V; Gibault L; Badoual C; Pintilie E; Hofman P; Monnet I; Scherpereel A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Mol Oncol; 2020 Jun; 14(6):1207-1223. PubMed ID: 32083805
[TBL] [Abstract][Full Text] [Related]
56. Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma.
Arulananda S; Thapa B; Walkiewicz M; Zapparoli GV; Williams DS; Dobrovic A; John T
J Thorac Oncol; 2018 Oct; 13(10):1588-1594. PubMed ID: 30056163
[TBL] [Abstract][Full Text] [Related]
57. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
Sneddon S; Patch AM; Dick IM; Kazakoff S; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
BMC Cancer; 2017 Jun; 17(1):396. PubMed ID: 28577549
[TBL] [Abstract][Full Text] [Related]
58. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
Kittaneh M; Berkelhammer C
J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
60. Italian pool of asbestos workers cohorts: mortality trends of asbestos-related neoplasms after long time since first exposure.
Ferrante D; Chellini E; Merler E; Pavone V; Silvestri S; Miligi L; Gorini G; Bressan V; Girardi P; Ancona L; Romeo E; Luberto F; Sala O; Scarnato C; Menegozzo S; Oddone E; Tunesi S; Perticaroli P; Pettinari A; Cuccaro F; Mattioli S; Baldassarre A; Barone-Adesi F; Cena T; Legittimo P; Marinaccio A; Mirabelli D; Musti M; Pirastu R; Ranucci A; Magnani C;
Occup Environ Med; 2017 Dec; 74(12):887-898. PubMed ID: 28775133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]